A new era of antibody research, development and commercialisation has already begun in Asia. Brimming with new R&D breakthroughs, a bio-specialised talented workforce, expansion of world-class clinical trials and production, and not forgetting the significantly lower cost of production, Asia has become the focus of Big Pharmas in their business development and R&D strategies.
In light of this, how do you capture the latest advancements and opportunities for monoclonal antibodies (mAbs) in Asia?
In an interview with Dr Francisco Leon, Vice President & Head Immunology Translational Medicine, Johnson & Johnson, Francisco sheds his insights on mAbs in Asia and the global scene.
The emergence of Asian powers is highlighted, particularly South Korea and China (with bio-similars) and India (also with innovative mAbs). Francisco also discussed issues like how translational strategies help in the development of monoclonal antibodies and requirements for payers in Asia to reimburse the cost of mAbs.
Dr Francisco Leon will be speaking at Asia Antibody Congress 2013 coming 17-20 June 2013 at Grand Copthorne Waterfront Hotel. Asia Antibody Congress 2013 is a strategic platform for pharmas, biotechs, research institutes and solution providers to discuss key strategies to expedite business development, scientific advancement and partnerships for their antibody business.